November 19, 2026

October 27, 2026

AdipoPharma Advances PATAS into Phase 1b Clinical Trial in Patients with Type 2 Diabetes

First participants with Type 2 diabetes dosed in multiple ascending dose (MAD) study evaluating AdipoPharma’s first-in-class insulin sensitizer Advancement follows successful completion of the single ascending dose (SAD) phase, where PATAS was well tolerated with no serious adverse events STRASBOURG, France, Oct. 27, 2026 (GLOBE NEWSWIRE) — AdipoPharma, a clinical-stage biotechnology company developing therapies that […]

Read More